Notable breakthroughs have occurred in AML immunotherapy and targeted therapy, particularly with the development of Fms Related Receptor Tyrosine Kinase 3 (FLT-3) inhibitors and Isocitrate Dehydrogenase (NADP (+)) 1/2 (IDH1/2) inhibitors (Kayser and Levis, 2022; Barrett, 2020). This evidence concerns the gene FLT3 and acute myeloid leukemia.